Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial

AI Briefing

• – Phase 1/2 INSPIRE DUCHENNE trial update: 40 participants dosed with SGT-003 to date.
• – Interim positive clinical update expected for the trial.
• – SGT-003 is being investigated as a potential treatment for Duchenne muscular dystrophy.